PANORAMIC
Research type
Research Study
Full title
Platform Adaptive trial of NOvel antiviRals for eArly treatMent of covid-19 In the Community
IRAS ID
1004274
Contact name
Christopher Butler
Contact email
Eudract number
2021-005748-31
ISRCTN Number
ISRCTN30448031
Research summary
Despite high uptake of COVID-19 vaccines, the disease remains prevalent around the world, with many patients experiencing considerable morbidity and requiring hospital admission. There is therefore an urgent need to identify treatments for COVID-19 for use in the community early on in the illness that speeds recovery and prevents the need for hospital admission.
We propose to use a platform randomised trial in primary care and the community to investigate the effectiveness of novel antivirals in preventing hospitalisations and/ or death in patients with confirmed COVID-19, who have a higher risk of an adverse outcome. A “platform trial” is a trial in which multiple treatments for the same disease can be tested simultaneously, and in which new interventions can be added or replace existing ones during the course of the trial in accordance with pre-specified criteria. Each new anti-viral treatment for investigation will be specified The Antivirals Taskforce.
Participants will be recruited in the community via different pathways, including signposting from clinicians and social media and national media outlets as well as from PANORAMIC Hubs. Alternatively, patients can self-refer to the trial by completing registration and screening questions either on our web-based platform or with a member of the trial team. Participants will complete a daily symptom diary for 28 days, and then be followed up at 3, 6 and 12-months by a trial team member. We will also follow-up patients long-term for up to 10 years by collecting data from routine clinical records.
REC name
South Central - Berkshire Research Ethics Committee
REC reference
21/SC/0393
Date of REC Opinion
19 Nov 2021
REC opinion
Further Information Favourable Opinion